Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 45
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

  • Massanella, Marta|||0000-0002-3326-151X
  • Ouchi, Dan|||0000-0002-8630-152X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Buzón, Maria José|||0000-0003-4427-9413
  • Richman, Douglas D.
  • Orna, Elisa|||0000-0002-6862-9636
  • Stevenson, Mario
  • Gatell, José Mª|||0000-0002-4705-3244
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
Background: HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART with raltegravir reduced CD8 T-cell activation in the Discor-Ral and IntegRal studies, we have evaluated the effect of raltegravir intensification on several soluble inflammation markers in these studies. Methods: Longitudinal plasma samples (0-48 weeks) from the IntegRal (n=67, 22 control and 45 intensified individuals) and the Discor-Ral studies (44 individuals with CD4 T-cell counts,350 cells/μl, 14 control and 30 intensified) were assayed for 25 markers. Mann-Whitney, Wilcoxon, Spearman test and linear mixed models were used for analysis. Results: At baseline, different inflammatory markers were strongly associated with HCV co-infection, lower CD4 counts and with cART regimens (being higher in PI-treated individuals), but poorly correlated with detection of markers of residual viral replication. Although raltegravir intensification reduced inflammation in individuals with lower CD4 T-cell counts, no effect of intensification was observed on plasma markers of inflammation in a global analysis. An association was found, however, between reductions in immune activation and plasma levels of the coagulation marker D-dimer, which exclusively decreased in intensified patients on protease inhibitor (PI)-based cART regimens (P=0.040). Conclusions: The inflammatory profile in treated HIV-infected individuals showed a complex association with HCV co-infection, the levels of CD4 T cells and the cART regimen. Raltegravir intensification specifically reduced D-dimer levels in PI-treated patients, highlighting the link between cART composition and residual viral replication; however, raltegravir had little effect on other inflammatory markers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

  • Real, Luis M.|||0000-0003-4932-7429
  • Neukam, Karin
  • Herrero del Rio, Mª del Rocío|||0000-0002-9678-0309
  • Guardiola, Josep M.
  • Reiberger, Thomas|||0000-0002-4590-3583
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Salazar, Juliana|||0000-0002-3581-4499
  • Mandorfer, Mattias|||0000-0003-2330-0017
  • Merino, Dolores
  • Soriano, Vicente|||0000-0002-4624-5199
  • Rivero Román, Antonio|||0000-0002-8643-4250
  • Macías, Juan|||0000-0002-4778-790X
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Caruz, Antonio
Objectives: The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients. Recently, a functional variant, ss469415590, in linkage disequilibrium (LD) with rs12979860, has been discovered. Our objective was to assess the value of ss469415590 to predict SVR to pegIFN/RBV in Caucasian HCV-1/4-infected individuals and to compare its performance with that of rs12979860. Methods: 272 Caucasian HCV-1/4-infected patients who completed a course of pegIFN/RBV were genotyped for both rs12979860 and ss469415590 markers. Logistic regression models including factors with univariate association with SVR and each genetic marker were elaborated. The area under the receiver operating-characteristic curve (AUROC) was calculated for each model and both were compared. Results: Both markers were in LD (r = 0.82). For rs12979860, 66 (64.0%) CC versus 56 (33.1%) T allele carriers achieved SVR (Adjusted OR = 4.156, 95%CI = 2.388-7.232, p = 4.647×10). For ss469415590, 66 (66.0%) TT/TT versus 56 (32.5%) -G allele carriers (Adjusted OR = 4.783, 95% CI = 2.714-8.428, p = 6.153×10) achieved SVR. The AUROC of the model including rs12979860 was 0.742 (95%CI = 0.672-0.813) and of that based on ss469415590 was 0.756 (95%CI = 0.687-0.826) (p = 0.780). Conclusions: The ss469415590 variant shows an equivalent performance to predict SVR to pegIFN/RBV than the rs2979860 in Caucasian HCV-1/4-infected patients. © 2014 Real et al.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe

  • Rivero-Juárez, Antonio
  • Frias, Mario
  • Pérez, Ana Belén
  • Pineda, Juan Antonio
  • Reina, Gabriel
  • Fuentes-López, Ana
  • Freyre Carrillo, Carolina
  • Ramirez-Arellano, Encarnación
  • Alados Arboledas, Juan Carlos
  • Rivero, Antonio
  • GEHEP-014
  • HEPAVIR
Background & Aim: Hepatitis E virus (HEV) was considered the only member of the Hepeviridae family with zoonotic potential. Nevertheless, this consideration has been reassessed owing to several reported cases of acute and chronic hepatitis linked to the Orthohepevirus C genus. Because the circulation of Orthohe-pevirus C in rodents has been described worldwide, the risk of zoonotic transmission is plausibly global. Methods: Orthohepevirus C RNA was retrospectively evaluated in 2 cohorts of patients in Spain. The first cohort included patients with acute hepatitis without etiological diagnosis after screening for hepatotropic virus infection. The second cohort included patients diagnosed with acute HEV infection, defined as positivity for anti-HEV-IgM antibodies and/or detectable HEV RNA in serum. Results: Cohort 1 comprised 169 patients (64.4% male, median age 43 years) and cohort 2 comprised 98 individuals (68.3% male, median age 45 years). Of the individuals included in Cohort 1, two (1.18%; 95% CI 0.2-3.8) had detectable Orthohe-pevirus C RNA in serum. In Cohort 2, of the 98 included patients, 58 showed detectable HEV RNA, while 40 only showed positivity for IgM antibodies. Among those bearing only IgM antibodies, Orthohepevirus C RNA was detected in 1 (2.5%; 95% CI 0.06-13.1) individual. All strains were consistent with ge-notype C1. The infection resulted in mild self-limiting acute hepatitis in 2 patients. Infection caused severe acute hepatitis in the remaining patient who died as a result of liver and renal failure. Conclusions: We described 3 cases of Orthohepevirus C in pa-tients with acute hepatitis, resulting in the first description of this infection in Europe. The prevalence obtained in our study suggests that Orthohepevirus C could be an emerging disease in Europe. Lay summary: We describe the first cases of acute hepatitis related to rat hepatitis E virus in Europe. The prevalence found in our study suggest that rat hepatitis E virus could be considered an emerging disease in Europe. (C) 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch Lombarte, Oscar
  • Tarancón Diez, Laura
  • Pedreño Lopez, Nuria
  • Arenas Busto, Miguel
  • Alvaro, Tamara
  • Casado, Concepción
  • Olivares, Isabel
  • Vera, Mar
  • Rodríguez, Carmen
  • del Romero, Jorge
  • López Galíndez, Cecilio
  • Ruiz Mateos, Ezequiel
  • Prado, Julia G.
  • Pernas, María
Background Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. Results In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. Conclusions These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses., Instituto de Salud Carlos III | Ref. PI13/02269, Instituto de Salud Carlos III | Ref. PI17/00164, Instituto de Salud Carlos III | Ref. PI16/0684, Instituto de Salud Carlos III | Ref. PI19/01127, Ministerio de Economía y Competitividad | Ref. RD12/0017/0028, Ministerio de Economía y Competitividad | Ref. RD16/0025/0020, Generalitat de Catalunya | Ref. AGAUR-FI_B 00582, Agencia Estatal de Investigación | Ref. RYC-2015-18241, Agencia Estatal de Investigación | Ref. PID2019-107931GA-I00, Xunta de Galicia | Ref. ED431F 2018/08, Ministerio de Economía y Competitividad | Ref. RD16/0025/0041
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

  • Vázquez-Castellanos, J. F.
  • Serrano-Villar, S.
  • Latorre, A.
  • Artacho, A.
  • Ferrús, M. L.
  • Madrid, N.
  • Vallejo, Alejandro
  • Sainz, T.
  • Martínez-Botas, J.
  • Ferrando-Martínez, Sara
  • Vera, Mar
  • Dronda, Fernando
  • Leal, Mauel
  • Romero, Jorge del
  • Moreno, Santiago
  • Estrada Pérez, Vicente
  • Gosalbes, M. J.
  • Moya, A.
Altered interplay between gut mucosa and microbiota during treated HIV infection may possibly contribute to increased bacterial translocation and chronic immune activation, both of which are predictors of morbidity and mortality. Although a dysbiotic gut microbiota has recently been reported in HIV+ individuals, the metagenome gene pool associated with HIV infection remains unknown. The aim of this study is to characterize the functional gene content of gut microbiota in HIV+ patients and to define the metabolic pathways of this bacterial community, which is potentially associated with immune dysfunction. We determined systemic markers of innate and adaptive immunity in a cohort of HIV-infected individuals on successful antiretroviral therapy without comorbidities and in healthy non-HIV-infected subjects. Metagenome sequencing revealed an altered functional profile, with enrichment of the genes involved in various pathogenic processes, lipopolysaccharide biosynthesis, bacterial translocation, and other inflammatory pathways. In contrast, we observed depletion of genes involved in amino acid metabolism and energy processes. Bayesian networks showed significant interactions between the bacterial community, their altered metabolic pathways, and systemic markers of immune dysfunction. This study reveals altered metabolic activity of microbiota and provides novel insight into the potential host–microbiota interactions driving the sustained inflammatory state in successfully treated HIV-infected patients., This work was supported by “Generalitat Valenciana” (Prometeo/2009/092) and by the Spanish Ministry of Economy and Competitiveness (SAF2012-31187), Redes Temáticas de Investigación en SIDA (ISCIII RETIC RD12/0017/0029 and RD12/0017/0037), and Junta de Andalucia (Proyecto de Excelencia CTS-6313). J.F.V.C. was supported by a fellowship “Ayudas Predoctorales de Formación en Investigación en Salud” from the Instituto de Salud Carlos III, Spain. S.S.V. and T.S. were supported by a grant from the Spanish Ministry of Science and Innovation (Ayudas para Contratos de Formación en Investigación Río Hortega). S.F.M. holds a grant from the Fondo de Investigaciones Sanitarias (CD10/00382)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice

  • Broset, E.
  • Saubi, N.
  • Guitart, N.
  • Aguilo, N.
  • Uranga, S.
  • Kilpeläinen, A.
  • Eto, Y.
  • Hanke, T.
  • Gonzalo-Asensio, J.
  • Martín, C.
  • Joseph-Munné, J.
The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated Mycobacterium tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG (Mycobacterium bovis bacillus Calmette-Guérin). With the aim of using MTBVAC as a vector for a dual TB-HIV vaccine, we constructed the recombinant MTBVAC.HIVA 2auxo strain. First, we generated a lysine auxotroph of MTBVAC (MTBVAC¿lys) by deleting the lysA gene. Then the auxotrophic MTBVAC¿lys was transformed with the E. coli-mycobacterial vector p2auxo.HIVA, harboring the lysA-complementing gene and the HIV-1 clade A immunogen HIVA. This TB-HIV vaccine conferred similar efficacy to the parental strain MTBVAC against Mtb challenge in mice. MTBVAC.HIVA 2auxo was safer than BCG and MTBVAC in severe combined immunodeficiency (SCID) mice, and it was shown to be maintained up to 42 bacterial generations in vitro and up to 100 days after inoculation in vivo. The MTBVAC.HIVA 2auxo vaccine, boosted with modified vaccinia virus Ankara (MVA).HIVA, induced HIV-1 and Mtb-specific interferon-¿-producing T cell responses and polyfunctional HIV-1-specific CD8+ T cells producing interferon-¿ (IFN-¿), tumor necrosis factor alpha (TNF-a), and CD107a in BALB/c mice. Here we describe new tools to develop combined vaccines against TB and HIV with the potential of expansion for other infectious diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand

  • Crichton, S.
  • Belfrage, E.
  • Collins, I.J.
  • Doerholt, K.
  • Judd, A.
  • Le Coeur, S.
  • Spoulou, V.
  • Goodall, R.
  • Scherpbier, H.
  • Smit, C.
  • Goetghebuer, T.
  • Gibb, D.M.
  • Noguera, A.
  • Navarro, M.L.
  • Ramos, J.T.
  • Galli, L.
  • Giaquinto, C.
  • Thorne, C.
  • Santa Ansone.
  • Marczynska, M.
  • Okhonskaia, L.
  • de Tejada, BM.
  • Jourdain, G.
  • Decker, L.
  • Ene, L.
  • Hainaut, M.
  • Van der Kelen, E.
  • Delforge, M.
  • de Martino, M.
  • Tovo, PA.
  • Patrizia, O.
  • Larovere, D.
  • Ruggeri, M.
  • Faldella, G.
  • Baldi, F.
  • Badolato, R.
  • Montagnani, C.
  • Venturini, E.
  • Lisi, C.
  • Di Biagio, A.
  • Taramasso, L.
  • Giacomet, V.
  • Erba, P.
  • Esposito, S.
  • Lipreri, R.
  • Salvini, F.
  • Tagliabue, C.
  • Cellini, M.
  • Bruzzese, E.
  • Lo Vecchio, A.
  • Rampon, O.
  • Dona, D.
  • Romano, A.
  • Dodi, I.
  • Maccabruni, A.
  • Consolini, R.
  • Bernardi, S.
  • Kuekou, HT.
  • Genovese, O.
  • Olmeo, P.
  • Cristiano, L.
  • Mazza, A.
  • Gabiano, C.
  • Garazzino, S.
  • Pellegatta, A.
  • Pajkrt, D.
  • Scherpbier, HJ.
  • Weijsenfeld, AM.
  • de Boer, CG.
  • Jurriaans, S.
  • Back, NKT.
  • Zaaijer, HL.
  • Berkhout, B.
  • Cornelissen, MTE.
  • Schinkel, CJ.
  • Wolthers, KC.
  • Fraaij, PLA.
  • van Rossum, AMC.
  • Vermont, CL.
  • van der Knaap, LC.
  • Visser, EG.
  • Boucher, CAB.
  • Koopmans, MPG.
  • van Kampen, JJA.
  • Pas, SD.
  • Henriet, SSV.
  • van de Flier, M.
  • van Aerde, K.
  • Strik-Albers, R.
  • Rahamat-Langendoen, J.
  • Stelma, FF.
  • Scholvinck, EH.
  • de Groot-de Jonge, H.
  • Niesters, HGM.
  • van Leer-Buter, CC.
  • Knoester, M.
  • Bont, LJ.
  • Geelen, SPM.
  • Wolfs, TFW.
  • Nauta, N.
  • Schuurman, R.
  • Verduyn-Lunel, F.
  • Wensing, AMJ.
  • Reiss, P.
  • Zaheri, S.
  • Bezemer, DO.
  • van Sighem, AI.
  • Smit, C.
  • Wit, FWMN.
  • Hillebregt, M.
  • de Jong, A.
  • Woudstra, T.
  • Bergsma, D.
  • Grivell, S.
  • Meijering, R.
  • Raethke, M.
  • Rutkens, T.
  • de Groot, L.
  • van den Akker, M.
  • Bakker, Y.
  • Bezemer, M.
  • El Berkaoui, A.
  • Geerlinks, J.
  • Koops, J.
  • Kruijne, E.
  • Lodewijk, C.
  • Lucas, E.
  • van der Meer, R.
  • Munjishvili, L.
  • Paling, E.
  • Peeck, B.
  • Ree, C.
  • Regtop, R.
  • Ruijs, Y.
  • van de Sande, L.
  • Schoorl, M.
  • Schnorr, P.
  • Tuijn, E.
  • Veenenberg, L.
  • van der Vliet, S.
  • Wisse, A.
  • Witte, EC.
  • Tuk, B.
  • Popielska, J.
  • Pokorska-Spiewak, M.
  • Oldakowska, A.
  • Zawadka, K.
  • Coupland, U.
  • Doroba, M.
  • Voronin, E.
  • Miloenko, M.
  • Labutina, S.
  • Soler-Palacin, P.
  • Frick, MA.
  • Perez-Hoyos, S.
  • Mur, A.
  • Lopez, N.
  • Mendez, M.
  • Mayol, L.
  • Vallmanya, T.
  • Calavia, O.
  • Garcia, L.
  • Coll, M.
  • Pineda, V.
  • Rius, N.
  • Rovira, N.
  • Duenas, J.
  • Gamell, A.
  • Fortuny, C.
  • Noguera-Julian, A.
  • Mellado, MJ.
  • Escosa, L.
  • Hortelano, MG.
  • Sainz, T.
  • Gonzalez-Tome, MI.
  • Rojo, P.
  • Blazquez, D.
  • Prieto, L.
  • Guillen, S.
  • Saavedra, J.
  • Santos, M.
  • Munoz, MA.
  • Ruiz, B.
  • Mc Phee, CF.
  • de Ory, SJ.
  • Alvarez, S.
  • Roa, MA.
  • Beceiro, J.
  • Martinez, J.
  • Badillo, K.
  • Apilanez, M.
  • Pocheville, I.
  • Garrote, E.
  • Colino, E.
  • Sirvent, JG.
  • Garzon, M.
  • Roman, V.
  • Montesdeoca, A.
  • Mateo, M.
  • Munoz, MJ.
  • Angulo, R.
  • Neth, O.
  • Falcon, L.
  • Terol, P.
  • Santos, JL.
  • Moreno, D.
  • Lendinez, F.
  • Grande, A.
  • Romero, FJ.
  • Perez, C.
  • Lillo, M.
  • Losada, B.
  • Herranz, M.
  • Bustillo, M.
  • Guerrero, C.
  • Collado, P.
  • Couceiro, JA.
  • Perez, A.
Objective: The aim of this study was to describe growth during puberty in young people with vertically acquired HIV. Design: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand. Methods: One thousand and ninety-four children initiating a nonnucleoside reverse transcriptase inhibitor or boosted protease inhibitor based regimen aged 1-10 years were included. Super Imposition by Translation And Rotation (SITAR) models described growth from age 8 years using three parameters (average height, timing and shape of the growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics associated with these three parameters. Results: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8, 9.0] years and -1.2 (IQR: -2.3 to -0.2), respectively. Median follow-up was 9.1 (IQR: 6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20-0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years and 1.50 (1.21-1.78) years later in those starting with HAZ less than -3 compared with HAZ at least -1. Later growth spurts in girls resulted in continued height growth into later adolescence. In boys starting ART with HAZ less than -1, growth spurts were later in children starting ART in the oldest age group, but for HAZ at least -1, there was no association with age. Girls and boys who initiated ART with HAZ at least -1 maintained a similar height to the WHO reference mean. Conclusion: Stunting at ART initiation was associated with later growth spurts in girls. Children with HAZ at least -1 at ART initiation grew in height at the level expected in HIV negative children of a comparable age.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez de Ory, Santiago
  • Ramos, José Tomas
  • Fortuny, Clàudia
  • González-Tomé, María Isabel
  • Mellado, Maria José
  • Moreno, David
  • Frick, Marie Antoinette
Retrospective study; Spanish Paediatric HIV Network; Rates of perinatal HIV, Estudio retrospectivo; Red Española de VIH Pediátrico; Tasas de VIH perinatal, Estudi retrospectiu; Xarxa espanyola de VIH Pediàtrica; Taxes de VIH perinatal, Background: There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods: A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results: A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions: A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact., This work has been partially funded by Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035, RD12/0017/0037 and RD16/0025/0019), project as part of the Plan R+D+I (2008-2011; 2013-2016) and cofinanced by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER), RISEPICLIN-19/2015, Fondo para la Investigación Sanitaria of the Spanish Ministry of Science and Innovation (FIS PI13/00422, PI16/01863), CYTED (214RT0482) and EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. COST CA17140 Cancer Nanomedicine-Front The Bench to Bebside. We thank the Spanish HIV HGM BioBank supported by ISC III project RETIC PT13/0010/0028 and PT17/0015/0042. No funding for this work was received from National Institutes of Health (NIH), Wellcome Trust and Howard Hughes Medical Institute (HHMI)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery

  • Massanella Luna, Marta, 1983-
  • Gomez, Elisabet|||0000-0002-9779-5940
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Curriu Martí, Marta
  • Ouchi, Dan|||0000-0002-8630-152X
  • Puig, Jordi|||0000-0002-4075-0346
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
BACKGROUND: High levels of ex vivo CD4 T-cell death and the accumulation of highly differentiated and/or immunosenescent T cells have been associated with poor CD4 T-cell recovery in treated HIV-infected individuals. However, the relationship between cell death and T-cell differentiation is still unclear. METHODS: We have analyzed cell death, immunosenescence and differentiation parameters in HAART-treated subjects (VL <50 copies/mL for more than 2 years) with CD4 T-cell count <350 cells/μL (immunodiscordant, n = 23) or.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART

  • Gómez, Carmen Elena
  • Perdiguero, Beatriz
  • García-Arriaza, Juan
  • Cepeda, Victoria
  • Sánchez-Sorzano, Carlos Óscar
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Jímenez, Jose Luis
  • Muñoz Fernández, María Ángeles
  • Gatell, José Mª|||0000-0002-4705-3244
  • López Bernaldo de Quirós, Juan Carlos|||0000-0002-8989-9758
  • Brander, Christian|||0000-0002-0548-5778
  • García, Felipe|||0000-0001-7658-5832
  • Esteban, Mariano|||0000-0003-0846-2827
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo,followed by interruption of HAART. METHODS: The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. RESULTS: MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. CONCLUSION: MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity. TRIAL REGISTRATION: ClinicalTrials. gov NCT01571466.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hidden costs of antiretroviral treatment, the public health efficiency of drug packaging

  • Andreu-Crespo, Àngels
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Cardona Peitx, Gloria
  • Sala-Piñol, Ferran
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Bonafont-Pujol, Xavier
While the overall percentage of unused antiretroviral medicines returned to the hospital pharmacy is low, their cost is quite high. Adverse events, treatment failure, pharmacokinetic interactions, pregnancy, or treatment simplification are common reasons for unplanned treatment changes. Socially inefficient antiretroviral packages prevent the reuse of drugs returned to the hospital pharmacy. We defined antiretroviral package categories based on the excellence of drug packaging and analyzed the number of pills and costs of drugs returned during a period of 1 year in a hospital-based HIV unit attending to 2,413 treated individuals. A total of 6,090 pills (34% of all returned antiretrovirals) - with a cost of 47,139.91€ - would be totally lost, mainly due to being packed up in the lowest efficiency packages. Newer treatments are packaged in low-excellence categories of packages, thus favoring the maintenance of these hidden costs in the near future. Therefore, costs of this low-efficiency drug packaging, where medication packages are started but not completed, in high-cost medications are substantial and should be properly addressed. Any improvement in the packaging by the manufacturer, and favoring the choice of drugs supplied through efficient packages (when efficacy, toxicity, and convenience are similar), should minimize the treatment expenditures paid by national health budgets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients

  • Falcon-Neyra, Lola
  • Palladino, Claudia
  • Navarro, Maria Luisa
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • González-Tomé, María Isabel
  • De Ory, Santiago J.
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Fortuny Guasch, Claudia
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Bermúdez Moreno, Elena
  • Santos, Juan Luis
  • Olbrich, Peter
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Briz, Verónica|||0000-0003-2297-5098
  • Neth, Olaf|||0000-0001-5018-0466
To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gp high cells and correlates with HIV-1 viral load

  • Minuesa, Gerard|||0000-0001-9911-8428
  • Arimany-Nardi, Cristina
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Moltó Marhuenda, José
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
To evaluate the role of P-glycoprotein (P-gp) and multidrug-resistant-protein 1 (MRP1) on raltegravir intracellular drug disposition in CD4+ T cells, investigate the effect of HIV-1 infection on P-gp expression and correlate HIV-1 viraemia with P-gp activity in primary CD4+ T cell subsets. The cellular accumulation ratio of [ 3 H]raltegravir was quantified in CD4+ T cell lines overexpressing either P-gp (CEM-P-gp) or MRP1 (CEM-MRP1) and in primary CD3+CD4+ T cells with high (P-gp high) and low P-gp activity (P-gp low); inhibition of efflux transporters was confirmed by the intracellular retention of calcein-AM. The correlation of P-gp activity with HIV-1 viraemia was assessed in naive and memory T cell subsets from 21 HIV-1-infected treatment-naive subjects. [ 3 H]Raltegravir cellular accumulation ratio decreased in CEM-P-gp cells (P < 0.0001). XR9051 (a P-gp inhibitor) and HIV-1 PIs reversed this phenomenon. Primary CD4+P-gp high cells accumulated less raltegravir (38.4% ± 9.6%) than P-gp low cells, whereas XR9051 also reversed this effect. In vitro HIV-1 infection of PBMCs and stimulation of CD4+ T cells increased P-gp mRNA and P-gp activity, respectively, while primary CD4+P-gp high T cells sustained a higher HIV-1 replication than P-gp low cells. A significant correlation between HIV-1 viraemia and P-gp activity was found in different CD4+ T cell subsets, particularly memory CD4+ T cells (r = 0.792, P < 0.0001). Raltegravir is a substrate of P-gp in CD4+ T cells. Primary CD4+P-gp high T cells eliminate intracellular raltegravir more readily than P-gp low cells and HIV-1 viraemia correlates with P-gp overall activity. Specific CD4+P-gp high T cell subsets could facilitate the persistence of viral replication in vivo and ultimately promote the appearance of drug resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4 + T cells on ART

  • Puertas, Maria C.|||0000-0002-6750-2318
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Massanella, Marta|||0000-0002-3326-151X
  • Pou, Christian|||0000-0003-3932-788X
  • Buzón, Maria José|||0000-0003-4427-9413
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Stevenson, Mario
  • Paredes, Roger|||0000-0002-6553-691X
  • Blanco, Julià|||0000-0002-2225-0217
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
In most patients, current antiretroviral therapy (ART) regimens can rapidly reduce plasma viral load. However, even after years of effective treatment, a significant proportion of patients show residual plasma viremia below the clinical detection limit. Although residual viremia might be associated with increased chronic immune activation and morbidity, its origin and its potential role in the replenishment of the viral reservoir during suppressive ART is not completely understood. We performed an in-depth genetic analysis of the total and episomal cell-associated viral DNA (vDNA) repertoire in purified CD4 + T cell subsets of three HIV-infected individuals, and used phylogenetic analysis to explore its relationship with plasma viruses. The predominant proviral reservoir was established in naïve or memory (central and transitional) CD4 + T cell subsets in patients harboring X4- or R5-tropic viruses, respectively. Regardless of the viral tropism, most plasma viruses detected under suppressive ART resembled the proviral reservoir identified in effector and transitional memory CD4 + T-cell subsets in blood, suggesting that residual viremia originates from these cells in either blood or lymphoid tissue. Most importantly, sequences in episomal vDNA in CD4 + T-cells were not well represented in residual viremia. Viral tropism determines the differential distribution of viral reservoir among CD4 + T-cell subsets. In spite of viral tropism, the effector and transitional memory CD4 + T-cells subsets are the main source of residual viremia during suppressive ART, even though their contribution to the total proviral pool is small. However, the lack of concordance between residual viremia and viral variants driving de novo infection of CD4 + T cells on ART may reflect the predominance of defective plasma HIV RNA genomes. These findings highlight the need for monitoring the multiple viral RNA/DNA persistence markers, based on their differential contribution to viral persistence. The online version of this article (doi:10.1186/s12977-016-0282-9) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Oral microbiome in HIV-associated periodontitis

  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Peterson, Jessica
  • Reznik, David
  • Harris, Erica V.
  • Joseph, Sandeep J.
  • Rivera, Javier
  • Kannanganat Sidharthan, Sunil|||0000-0003-4605-9799
  • Amara, Rama
  • Nguyen, Minh Ly
  • Mutembo, Simon
  • Paredes, Roger|||0000-0002-6553-691X
  • Read, Timothy D.
  • Marconi, Vincent C.
Supplemental Digital Content is available in the text HIV-associated periodontal diseases (PD) could serve as a source of chronic inflammation. Here, we sought to characterize the oral microbial signatures of HIV+ and HIV- individuals at different levels of PD severity. This cross-sectional study included both HIV+ and HIV- patients with varying degrees of PD. Two tooth, 2 cheek, and 1 saliva samples were obtained for microbiome analysis. Mothur/SILVADB were used to classify sequences. R/Bioconductor (Vegan, PhyloSeq, and DESeq2) was employed to assess overall microbiome structure differences and differential abundance of bacterial genera between groups. Polychromatic flow cytometry was used to assess immune activation in CD4 and CD8 cell populations. Around 250 cheek, tooth, and saliva samples from 50 participants (40 HIV+ and 10 HIV-) were included. Severity of PD was classified clinically as None/Mild (N), Moderate (M), and Severe (S) with 18 (36%), 16 (32%), and 16 (32%) participants in each category, respectively. Globally, ordination analysis demonstrated clustering by anatomic site (R 2 = 0.25, P < 0.001). HIV status and PD severity showed a statistically significant impact on microbiome composition but only accounted for a combined 2% of variation. HIV+ samples were enriched in genera Abiotrophia, Neisseria, Kingella, and unclassified Neisseriaceae and depleted in Leptotrichia and Selenomonas. The Neisseria genus was consistently enriched in HIV+ participants regardless of sampling site and PD level. Immune markers were altered in HIV+ participants but did not show association with the oral microbiome. HIV-associated changes in oral microbiome result in subtle microbial signatures along different stages of PD that are common in independent oral anatomic sites.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A baseline metabolomic signature is associated with immunological CD4 + T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Mallol, Roger
  • López Dupla, Miguel
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Blanco, Julià|||0000-0002-2225-0217
  • Cañellas, Nicolau
  • Rull, Anna|||0000-0002-8907-7754
  • Leal, Manuel
  • Correig, Xavier|||0000-0002-6902-3054
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Vidal, Francesc|||0000-0002-6692-6186
Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma HIV-1 Tropism and the Risk of Short- Term Clinical Progression to AIDS or Death

  • Casadellà, Maria|||0000-0002-4115-2305
  • Cozzi-Lepri, Alessandro|||0000-0002-6339-919X
  • Phillips, Andrew
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Bickel, Markus
  • Sedlacek, Dalibor
  • Zilmer, Kai
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Lundgren, Jens|||0000-0001-8901-7850
  • Paredes, Roger|||0000-0002-6553-691X
Objective. To investigate if plasma HIV-1 tropism testing could identify subjects at higher risk for clinical progression and death in routine clinical management. Design. Nested case-control study within the EuroSIDA cohort. Methods. Cases were subjects with AIDS or who died from any cause, with a plasma sample with HIV-1 RNA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status

  • Ceausu, Andra
  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Peraire, Joaquim|||0000-0001-7808-5479
  • López-Dupla, M.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Vidal-Gonzalez, J.
  • Perpiñán, C.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Veloso, S.
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Ruiz-Mateos, E.
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Vidal, Francisco|||0000-0001-8089-4945
  • Rull, A.
A relationship between polymorphisms in genes encoding interleukin 7 (IL-7) and its cellular receptor (IL-7R) and antiretroviral therapy (ART)-associated immune recovery in HIV subjects has been previously reported. However, details of this relationship remain unclear, and the association of these polymorphisms with circulating IL-7/IL-7R levels is scarce. Here, we explored whether IL-7/IL-7R axis was associated with quantitative CD4 T-cell recovery in HIV-infected subjects. IL-7/IL-7R polymorphisms were assessed by genotyping, and multiple inheritance models were used to estimate both, their association with low pre-ART CD4 T-cell counts and incomplete immune recovery status after 48 weeks of suppressive ART. Integrated data from genetic variants association and soluble plasma IL-7/IL-7R quantification suggest that IL-7/IL-7R genotype expression could alter the homeostatic balance between soluble and membrane-bound receptors. The haplotype analyses indicates that allele combinations impacts pre-ART circulating CD4 T-cell counts, immune recovery status and the absolute increment of CD4 T-cell counts. The knowledge about how IL-7/IL-7R axis is related to quantitative CD4 T-cell recovery and immune recovery status after initiating ART could be useful regarding T-cell reservoirs investigations in HIV subjects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez De Ory, S.
  • Ramos Amador, José Tomás
  • Fortuny Guasch, Claudia
  • González-Tomé, María Isabel
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Moreno Pérez, David|||0000-0002-7017-4095
  • Gavilán, C.
  • Menasalvas, A. I.
  • Piqueras, Ana Isabel
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Muñoz-Fernández, M. A.
  • Navarro, Maria Luisa
Background There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Balances, a New Perspective for Microbiome Analysis

  • Rivera Pinto, Javier|||0000-0002-4427-6442
  • Egozcue, Juan José|||0000-0002-5144-4483
  • Pawlowsky-Glahn, Vera|||0000-0001-9775-6434
  • Paredes, Roger|||0000-0002-6553-691X
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Calle, M. Luz|||0000-0001-9334-415X
We propose a new algorithm for the identification of microbial signatures. These microbial signatures can be used for diagnosis, prognosis, or prediction of therapeutic response based on an individual's specific microbiota. High-throughput sequencing technologies have revolutionized microbiome research by allowing the relative quantification of microbiome composition and function in different environments. In this work we focus on the identification of microbial signatures, groups of microbial taxa that are predictive of a phenotype of interest. We do this by acknowledging the compositional nature of the microbiome and the fact that it carries relative information. Thus, instead of defining a microbial signature as a linear combination in real space corresponding to the abundances of a group of taxa, we consider microbial signatures given by the geometric means of data from two groups of taxa whose relative abundances, or balance, are associated with the response variable of interest. In this work we present selbal, a greedy stepwise algorithm for selection of balances or microbial signatures that preserves the principles of compositional data analysis. We illustrate the algorithm with 16S rRNA abundance data from a Crohn's microbiome study and an HIV microbiome study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Urrea, Víctor|||0000-0002-2577-856X
  • Dalmau, Judith|||0000-0001-7513-3711
  • Lopez, Miguel
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Ouchi, Dan|||0000-0002-8630-152X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Passaes, Caroline|||0000-0002-0813-2521
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Saez-Cirion, Asier
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Esteller, M.|||0000-0003-4490-6093
  • Berdasco, Maria|||0000-0002-6750-0400
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
BACKGROUND: Human genetic variation-mostly in the human leukocyte antigen (HLA) and C-C chemokine receptor type 5 (CCR5) regions-explains 25% of the variability in progression of human immunodeficiency virus (HIV) infection. However, it is also known that viral infections can modify cellular DNA methylation patterns. Therefore, changes in the methylation of cytosine-guanine (CpG) islands might modulate progression of HIV infection. METHODS: In total, 85 samples were analyzed: 21 elite controllers (EC), 21 subjects with HIV before combination antiretroviral therapy (cART) (viremic, 93 325 human immunodeficiency virus type 1 [HIV-1] RNA copies/mL) and under suppressive cART (cART, median of 17 months, <50 HIV-1 RNA copies/mL), and 22 HIV-negative donors (HIVneg). We analyzed the methylation pattern of 485 577 CpG in DNA from peripheral CD4+ T lymphocytes. We selected the most differentially methylated gene (TNF) and analyzed its specific methylation, messenger RNA (mRNA) expression, and plasma protein levels in 5 individuals before and after initiation of cART. RESULTS: We observed 129 methylated CpG sites (associated with 43 gene promoters) for which statistically significant differences were recorded in viremic versus HIVneg, 162 CpG sites (55 gene promoters) in viremic versus cART, 441 CpG sites (163 gene promoters) in viremic versus EC, but none in EC versus HIVneg. The TNF promoter region was hypermethylated in viremic versus HIVneg, cART, and EC. Moreover, we observed greater plasma levels of TNF in viremic individuals than in EC, cART, and HIVneg. CONCLUSIONS: Our study shows that genome methylation patterns vary depending on HIV infection status and progression profile and that these variations might have an impact on controlling HIV infection in the absence of cART.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy, Comparison with a healthy control group in a 2-year prospective study

  • Di Yacovo, Silvana
  • Saumoy, Maria|||0000-0002-0047-1991
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Navarro-Alcaraz, Antonio|||0000-0002-1118-8972
  • Sviridov, Dmitri
  • Javaloyas, Manuel
  • Vila, Ramon
  • Vernet, Anton|||0000-0002-7028-1368
  • Low, Hann
  • Peñafiel, Judith|||0009-0006-6688-6395
  • García, Benito
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Podzamczer, Daniel|||0000-0001-7090-3561
To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients. We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

  • Medrano, Luz M.
  • Gutiérrez-Rivas, Mónica
  • Blanco, Julià|||0000-0002-2225-0217
  • García, Marcial
  • Jiménez-Sousa, María A.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Montero, Marta|||0000-0002-3432-5394
  • Iribarren, José Antonio
  • Bernal, Enrique|||0000-0002-4041-0579
  • Martínez, Onofre Juan
  • Benito, José Miguel|||0000-0002-7172-049X
  • Rallón, Norma|||0000-0002-4643-247X
  • Resino, Salvador|||0000-0001-8783-0450
The mitochondrial DNA (mtDNA) seems to influence in a large number of diseases, including HIV infection. Moreover, there is a substantial inter-individual variability in the CD4+ recovery in HIV-infected patients on combination antiretroviral therapy (cART). Our study aimed to analyze the association between mtDNA haplogroups and CD4+ recovery in HIV-infected patients on cART. This is a retrospective study of 324 naïve cART patients with CD4+ < 200 cells/mm 3, who were followed-up during 24 months after initiating cART. All patients had undetectable HIV viral load during the follow-up. Besides, we included 141 healthy controls. MtDNA genotyping was performed by using Sequenom's MassARRAY platform. The primary outcome variable was the slope of CD4+ recovery. Patients were stratified into two groups by the median slope value of CD4+ (9.65 CD4+ cells/mm 3 /month). Logistic regression analyses were performed to calculate the odds of CD4+ recovery according to mtDNA haplogroups. Our study included European HIV-infected patients within the N macro-cluster. The baseline values of CD4+ T-cells were similar between groups of patients stratified by the P50th of the slope of CD4+ T-cells recovery. Patients in the low CD4+ T-cells recovery group were older (p = 0.001), but this variable was included in the multivariate models. When we analyzed the frequencies of mtDNA haplogroups, no significant differences between HIV-infected individuals and healthy controls were found. We did not find any significant association between mtDNA haplogroups and the slope of CD4+ T-cells recovery by linear regression analysis. However, Patients carrying haplogroup H had a higher odds of having a better CD4+ recovery (> 9.65 CD4+ cells/mm 3 /month) than patients without haplogroup H (p = 0.032). The adjusted logistic regression showed that patients carrying haplogroup H had a higher likelihood of achieving a CD4+ recovery > 9.65 CD4+ cells/mm 3 /month [adjusted odds ratio (aOR) = 1.75 (95% CI = 1.04; 2.95); p = 0.035]. European mitochondrial haplogroup H was associated with the improved CD4+ recovery in HIV-infected patients starting cART with CD4+ < 200 cells/mm 3.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus

  • Carrillo-Salinas, Francisco J.|||0000-0002-7936-5859
  • Mestre, Leyre|||0000-0001-6970-2316
  • Mecha, Miriam
  • Feliú, Ana|||0000-0002-1157-1525
  • del Campo, Rosa|||0000-0003-1147-7923
  • Villarrubia, Noelia
  • Espejo, Carmen|||0000-0001-9949-5901
  • Montalban, Xavier|||0000-0002-0098-9918
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Villar, L. M.
  • Guaza, Carmen|||0000-0003-3240-9807
Recent studies have begun to point out the contribution of microbiota to multiple sclerosis (MS) pathogenesis. Theiler's murine encephalomyelitis virus induced demyelinating disease (TMEV-IDD) is a model of progressive MS. Here, we first analyze the effect of intracerebral infection with TMEV on commensal microbiota and secondly, whether the early microbiota depletion influences the immune responses to TMEV on the acute phase (14 dpi) and its impact on the chronic phase (85 dpi). The intracranial inoculation of TMEV was associated with a moderate dysbiosis. The oral administration of antibiotics (ABX) of broad spectrum modified neuroimmune responses to TMEV dampening brain CD4 + and CD8 + T infiltration during the acute phase. The expression of cytokines, chemokines and VP2 capsid protein was enhanced and accompanied by clusters of activated microglia disseminated throughout the brain. Furthermore, ABX treated mice displayed lower levels of CD4 + and CD8 + T cells in cervical and mesenteric lymph nodes. Increased mortality to TMEV was observed after ABX cessation at day 28pi. On the chronic phase, mice that survived after ABX withdrawal and recovered microbiota diversity showed subtle changes in brain cell infiltrates, microglia and gene expression of cytokines. Accordingly, the surviving mice of the group ABX-TMEV displayed similar disease severity than TMEV mice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers

  • Vesterbacka, Jan
  • Rivera, Javier
  • Noyan, Kajsa
  • Parera, Mariona|||0000-0002-0756-8307
  • Neogi, Ujjwal
  • Calle, M. Luz|||0000-0001-9334-415X
  • Paredes, Roger|||0000-0002-6553-691X
  • Sönnerborg, Anders
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Nowak, Piotr|||0000-0003-2747-0734
Gut microbiota dysbiosis features progressive HIV infection and is a potential target for intervention. Herein, we explored the microbiome of 16 elite controllers (EC), 32 antiretroviral therapy naive progressors and 16 HIV negative controls. We found that the number of observed genera and richness indices in fecal microbiota were significantly higher in EC versus naive. Genera Succinivibrio, Sutterella, Rhizobium, Delftia, Anaerofilum and Oscillospira were more abundant in EC, whereas Blautia and Anaerostipes were depleted. Additionally, carbohydrate metabolism and secondary bile acid synthesis pathway related genes were less represented in EC. Conversely, fatty acid metabolism, PPAR-signalling and lipid biosynthesis proteins pathways were enriched in EC vs naive. The kynurenine pathway of tryptophan metabolism was altered during progressive HIV infection, and inversely associated with microbiota richness. In conclusion, EC have richer gut microbiota than untreated HIV patients, with unique bacterial signatures and a distinct metabolic profile which may contribute to control of HIV.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4 + T-cell immune recovery

  • Gomez, Elisabet|||0000-0002-9779-5940
  • García Rodríguez, Elisabet
  • Urrea, Víctor|||0000-0002-2577-856X
  • Massanella, Marta|||0000-0002-3326-151X
  • Puig, Jordi|||0000-0002-4075-0346
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
Poor CD4 + T-cell recovery after cART has been associated with skewed T-cell maturation, inflammation and immunosenescence; however, T-cell functionality in those individuals has not been fully characterized. In the present study, we assessed T-cell function by assessing cytokine production after polyclonal, CMV and HIV stimulations of T-cells from ART-suppressed HIV-infected individuals with CD4 + T-cell counts.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4 + T-cell immune recovery

  • Gomez, Elisabet|||0000-0002-9779-5940
  • Massanella, Marta|||0000-0002-3326-151X
  • García Rodríguez, Elisabet
  • Giles, David
  • Bernadó, Marta
  • Urrea, Víctor|||0000-0002-2577-856X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Ouchi, Dan|||0000-0002-8630-152X
  • Puig, Jordi|||0000-0002-4075-0346
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
Some HIV-infected c-ART-suppressed individuals show incomplete CD4 + T-cell recovery, abnormal T-cell activation and higher mortality. One potential source of immune activation could be coinfection with cytomegalovirus (CMV). IgG and IgM levels, immune activation, inflammation and T-cell death in c-ART-suppressed individuals with CD4 + T-cell counts.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013

  • Jiménez de Ory, Santiago
  • González-Tomé, María Isabel
  • Fortuny Guasch, Claudia
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Bustillo, Matilde
  • Ramos Amador, José Tomás
  • Muñoz-Fernández, Maria Angeles
  • Navarro, Maria Luisa
Vertical human immunodeficiency virus (HIV) infection has decreased in industrialized countries in recent decades, but there are no studies on the mechanisms of HIV transmission among infected children in Spain. Our aim was to study the characteristics and trends of diagnoses of vertically HIV-infected children in Spain from 2004 to 2013. Vertically HIV-infected children were selected if they were diagnosed from 2004 to 2013, were aged 0 to 18 years old, and were included in the Cohort of the Spanish Pediatric HIV Network (CoRISpe). Demographic, clinical, immunological, and virological data at diagnosis were obtained. The rate of diagnoses of vertically HIV-infected children was calculated as the number of cases per 100,000 inhabitants. Obstetric data of mothers of Spanish children and prophylaxis at childbirth and postpartum were obtained. A total of 218 HIV-infected children were included in the study. Of this sample, 182 children (83.5%) were perinatally HIV infected, and 125 out of those 182 children (68.7%) were born in Spain. The vertically HIV-infected Spanish children were diagnosed earlier and were in better clinical and immunological condition at diagnosis than were foreign children. The rate of vertically HIV-infected children declined from 0.09 in 2004 to 0.03 in 2013 due to the decrease in the rate of children born in Spain (0.08 in 2004 vs 0.01 in 2013). A total of 60 out of 107 mothers (56.1%) of Spanish children were diagnosed at or after childbirth. However, this number declined between 2004 and 2013. The rate of new HIV diagnoses of vertically HIV-infected children decreased significantly between 2004 and 2013 from 0.09 to 0.03 per 100,000 inhabitants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels

  • López-Dupla, Miguel
  • Maymó-Masip, Elsa
  • Martínez, Esteban|||0000-0002-6911-8846
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Leal, Manuel
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Arnedo, Mireia|||0000-0001-6248-7780
  • Ferrando-Martínez, Sara
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Alba, Verónica|||0000-0002-5925-9573
  • Gatell, José Mª|||0000-0002-4705-3244
  • Vendrell, Joan|||0000-0002-6994-6115
  • Vidal, Francesc|||0000-0002-6692-6186
  • Chacón, Matilde R.
Obesity and HIV-1/HAART-associated lipodystrophy syndrome (HALS) share clinical, pathological and mechanistic features. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that plays an important role in obesity and related diseases. We sought to explore the relationship between HALS and circulating levels of soluble (s) TWEAK and its scavenger receptor sCD163. This was a cross-sectional multicenter study of 120 HIV-1-infected patients treated with a stable HAART regimen; 56 with overt HALS and 64 without HALS. Epidemiological and clinical variables were determined. Serum levels of sTWEAK and sCD163 levels were measured by ELISA. Results were analyzed with Student's t -test, Mann-Whitney U and χ 2 test. Pearson and Spearman correlation were used to estimate the strength of association between variables. Circulating sTWEAK was significantly decreased in HALS patients compared with non-HALS patients (2.81±0.2 vs. 2.94±0.28 pg/mL, p = 0.018). No changes were observed in sCD163 levels in the studied cohorts. On multivariate analysis, a lower log sTWEAK concentration was independently associated with the presence of HALS (OR 0.027, 95% CI 0.001-0.521, p = 0.027). HALS is associated with decreased sTWEAK levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Villarroya, Joan
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Torres, Ferran|||0000-0002-7355-7913
  • Campderrós, Laura
  • Gallego-Escuredo, José Miguel
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Corbacho, Noemí
  • Vidal, Francesc|||0000-0002-6692-6186
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Girlat, Marta|||0000-0001-7968-4190
Objective: People living with HIV (PLWH) have an increased cardiovascular risk (CVR) owing to dyslipidemia, insulin resistance, metabolic syndrome, and HIV/combination antiretroviral therapy (cART)-associated lipodystrophy (HALS). Atherosclerosis and inflammation are related to growth differentiation factor-15 (GDF15). The relationship between metabolic disturbances, HALS, and CVR with GDF15 in PLWH is not known. Research design and methods: Circulating GDF15 levels in 152 PLWH (with HALS = 60, without HALS = 43, cART-naïve = 49) and 34 healthy controls were assessed in a cross-sectional study. Correlations with lipids, glucose homeostasis, fat distribution, and CVR were explored. Results: PLWH had increased circulating GDF15 levels relative to controls. The increase was the largest in cART-treated PLWH. Age, homeostatic model assessment of insulin resistance 1 (HOMA1-IR), HALS, dyslipidemia, C-reactive protein, and CVR estimated with the Framingham score correlated with GDF15 levels. The GDF15-Framingham correlation was lost after age adjustment. No correlation was found between GDF15 and the D:A:D Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score estimated CVR. CVR independent predictors were patient group (naïve, HALS-, and HALS+) and cumulated protease inhibitor or nucleoside reverse transcriptase inhibitor exposure. Conclusions: PLWH, especially when cART-treated, has increased GDF15 levels-this increase is associated with dyslipidemia, insulin resistance, metabolic syndrome, HALS, and inflammation-related parameters. GDF15 is unassociated with CVR when age-adjusted.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters, results from a multicentre cohort study, 2004-2018

  • Domínguez-Domínguez, Lourdes|||0000-0001-6018-9026
  • Rava, Marta|||0000-0003-2260-9370
  • Bisbal, Otilia|||0000-0003-3746-3378
  • Lopez-Cortés, Luis
  • Portilla, Joaquín|||0000-0002-3676-9511
  • Podzamczer, Daniel|||0000-0001-7090-3561
  • Olalla, Julián
  • Fuster, Daniel|||0000-0003-1262-5860
  • Rubio, Rafael
  • Jarrín, Inmaculada
  • Iribarren, José Antonio
  • Moreno, Santiago|||0000-0002-2843-1094
To study whether the association between the CD4/CD8 ratio variation over time and the development of clinical outcomes vary in late presenters (CD4 count < 350/µL or AIDS event at enrolment) or advanced presenters (CD4 count < 200/µL or AIDS event at enrolment). We included ART-naïve adults from the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) enrolled between January 2004 up to November 2018 and with at least 6 months of follow-up. We used extended Cox proportional hazard models to estimate the hazard ratios (HRs) for the association between CD4/CD8 ratio over time and a composite endpoint of the occurrence of the first AIDS event, first serious non-AIDS event or overall mortality occurring from 6 months after enrolment. HRs in non-late, late and advanced presenters were obtained by including an interaction term between late presentation status and CD4/CD8 ratio over time. Of 10,018 participants, 55.6% were late presenters and 26.5% were advanced presenters. Compared with CD4/CD8 ratio > 0.4, CD4/CD8 ratio ≤ 0.4 over time was associated with an increased risk of experiencing the composite endpoint in non-late (HR 1.90; 95%CI 1.48, 2.43), late (HR 1.94; 1.46, 2.57) and advanced presenters (HR 1.72; 1.26, 2.34). Similarly, CD4/CD8 ratio ≤ 0.4 over time was associated with a higher risk of developing an AIDS event (HR 3.31; 2.23, 4.93 in non-late; HR 2.75; 1.78, 4.27 in late and HR 2.25; 1.34, 3.76 in advanced presenters) or serious non-AIDS event (HR 1.39; 0.96, 2.02 in non-late, HR 1.62; 1.10, 2.40 in late and HR 1.49; 0.97, 2.29 in advanced presenters) as well as with a higher risk of overall mortality (HR 1.49; 0.92, 2.41 in non-late, HR 1.80; 1.04, 3.11 in late and HR 1.61; 0.92, 2.83 in advanced presenters) compared to CD4/CD8 > 0.4, regardless of the late presentation status. A low CD4/CD8 measured over time is associated with increased risk of morbidity and mortality in people living with HIV independently of their late presentation status. These data support the prognostic role of CD4/CD8 over time and can help defining a subgroup of patients who need closer monitoring to avoid comorbidities. The online version contains supplementary material available at 10.1186/s12879-022-07352-z.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Tarancon-Diez, Laura
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Arenas, Miguel
  • Alvaro, Tamara
  • Casado, Concepcion
  • Olivares, Isabel
  • Vera, Mar|||0000-0002-3841-7747
  • Rodriguez, Carmen
  • Del Romero, Jorge
  • López-Galíndez, Cecilio|||0000-0002-2324-9584
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Prado, Julia G.|||0000-0002-5439-4645
  • Pernas, María
Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses. The online version contains supplementary material available at 10.1186/s12977-022-00591-7.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expression of Chimeric HPV-HIV Protein L1P18 in Pichia pastoris, Purification and Characterization of the Virus-like Particles

  • Eto, Yoshiki
  • Saubi, Narcis|||0000-0001-5493-1044
  • Ferrer, Pau|||0000-0002-5287-4127
  • Joseph-Munné, Joan
Currently, three human papillomavirus (HPV) vaccines are already licensed and all of them are based on virus-like particles (VLPs) of HPV L1 capsid protein but not worldwide accessible. While about 38.0 million people were living with HIV in 2019, only 68% of HIV-infected individuals were accessing antiretroviral therapy as of the end of June 2020 and there is no HIV vaccine yet. Therefore, safe, effective, and affordable vaccines against those two viruses are immediately needed. Both HPV and HIV are sexually transmitted infections and one of the main access routes is the mucosal genital tract. Thus, the development of a combined vaccine that would protect against HPV and HIV infections is a logical effort in the fight against these two major global pathogens. In this study, a recombinant Pichia pastoris producing chimeric HPV-HIV L1P18 protein intracellularly was constructed. After cell disruption, the supernatant was collected, and the VLPs were purified by a combination of ammonium sulfate precipitation, size exclusion chromatography, ultracentrifugation, and ultrafiltration. At the end of purification process, the chimeric VLPs were recovered with 96% purity and 9.23% overall yield, and the morphology of VLPs were confirmed by transmission electron microscopy. This work contributes towards the development of an alternative platform for production of a bivalent vaccine against HPV and HIV in P. pastoris.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned

  • Eto, Yoshiki
  • Saubi, Narcis|||0000-0001-5493-1044
  • Ferrer, Pau|||0000-0002-5287-4127
  • Joseph, Joan
Virus-like particles (VLPs) are a type of subunit vaccine which resembles viruses but do not contain any genetic material so that they are not infectious. VLPs maintain the same antigenic conformation to the original virus, and they could be a better vaccine candidate than live-attenuated and inactivated vaccines. In addition, compared to other subunit vaccines such as soluble protein, VLPs can stimulate both innate and adaptive immune responses effectively and safely against several pathogens by the closer morphology to its native virus. They have already been licensed as vaccines against Hepatitis B virus, human papillomavirus (HPV), and several veterinary diseases. Moreover, it has been investigated to prevent other viral infections including HIV. While HIV VLP-based vaccines have been studied over 35 years, none of them has been successful enough to reach even Phase III clinical trials. In this review, we summarize: (i) general features of VLPs; (ii) epidemiological data and current status of vaccine research and development on HPV and HIV; and (iii) previous studies held on HPV VLPs, HIV VLPs, and chimeric HPV/HIV VLPs including production methods and different animal immunization assays. Furthermore, we review present state of human clinical trials with VLPs and consider the potential to develop a successful preventive HIV vaccine using HPV VLP models. Finally, we discuss the benefits, limitations, and challenges of developing chimeric VLPbased HPV/HIV vaccines with recent findings, critical issues to improve VLP-based vaccines, and hot topics for the next 5 years to join the global effort to fight against these two pathogens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors

  • Alejos, Belén|||0000-0001-9571-6471
  • Suárez-García, Inés|||0000-0002-7016-716X
  • Bisbal, Otilia|||0000-0003-3746-3378
  • Iribarren, José Antonio
  • Asensi, Víctor
  • Górgolas, Miguel
  • Muga, Roberto|||0000-0001-6301-431X
  • Moreno, Santiago|||0000-0002-2843-1094
  • Jarrín, Inma|||0000-0002-7485-2252
Background We aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regimens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with the choice of each regimen. Methods We analyzed initial ART regimens prescribed in adults participating in CoRIS from 2014 to 2017. Only regimens prescribed in >5% of patients were considered. We used multivariable multinomial regression to estimate Relative Risk Ratios (RRRs) for the association between sociodemographic and clinical characteristics and the choice of the initial regimen. Results Among 2874 participants, abacavir(ABC)/lamivudine(3TC)/dolutegavir(DTG) was the most frequently prescribed regimen (32.1%), followed by tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir(EVG)/cobicistat(COBI) (14.9%), TDF/FTC/rilpivirine (RPV) (14.0%), tenofovir alafenamide (TAF)/FTC/EVG/COBI (13.7%), TDF/FTC+DTG (10.0%), TDF/FTC+darunavir/ritonavir or darunavir/cobicistat (bDRV) (9.8%) and TDF/FTC+raltegravir (RAL) (5.6%). Compared with ABC/3TC/DTG, starting TDF/FTC/RPV was less likely in patients with CD4100.000 copies/mL. TDF/FTC+DTG was more frequent in those with CD4100.000 copies/mL. TDF/FTC+RAL and TDF/FTC+bDRV were also more frequent among patients with CD4 Conclusions The choice of initial ART regimens is consistent with Spanish guidelines' recommendations, but is also clearly influenced by physician's perception based on patient's clinical and sociodemographic variables and by the prescribing hospital location.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5, Prognostic signature of immune recovery status in treated HIV-positive patients

  • Yeregui, Elena|||0000-0003-2994-4219
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Ceausu, Andra
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Inciarte, Alexy|||0000-0003-1896-3457
  • Vidal-González, Judit
  • Peraire, Maria
  • Perpiñán, Carles|||0000-0003-2398-3276
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Masip, Jenifer|||0000-0002-9233-5195
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Martí, Anna
  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
The underlying mechanisms of incomplete immune reconstitution in treated HIV-positive patients are very complex and may be multifactorial, but perturbation of chemokine secretion could play a key role in CD4 T-cell turnover. We evaluated the circulating baseline and 48-week follow-up concentrations of SDF-1/CXCL12, fractalkine/CX3CL1, MCP-1/CCL2, MIP-α/CCL3, MIP-β/CCL4 and RANTES/CCL5, and we estimated their association with CXCL12, CX3CR1, CCR2, CCL5 and CCR5 single nucleotide polymorphisms (SNPs) to investigate multiple chemokine-chemokine receptor signatures associated with immune dysregulation preceding poor immune recovery. The circulating concentrations and gene expression patterns of SDF-1/CXCL12 (CXCL12 rs1801157) and MCP-1/CCL2 (CCR2 rs1799864_814) were associated with immune recovery status. CCR2 rs1799864_814 and CCR5 rs333_814 (Δ32) determine the baseline plasma RANTES and MIP-α concentrations, respectively, in participants with poor immune response. SDF-1/CXCL12 and MCP-1/CCL2 could be considered prognostic markers of immune failure despite suppressive antiretroviral therapy. The strong linkage disequilibrium (LD) between CCR2 rs1799864_814 and CCR5 rs1800024 indicated that the alleles of each gene are inherited together more often than would be expected by chance. This work was supported by Fondo de Investigacion Sanitaria and SPANISH AIDS Research Network (ISCIII-FEDER); AGAUR and Gilead Fellowship. FV and YMP are supported by grants from the Programa de Intensificación (ISCIII) and Servicio Andaluz de Salud, respectively. JVG,EY and LR are supported by the Instituto de Salud Carlos III (ISCIII). AR is supported by Departament de Salut, Generalitat de Catalunya and by the Instituto de Salud Carlos III (ISCIII).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Von Wichmann, Miguel Ángel
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador|||0000-0001-8783-0450
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Miralles, Pilar
  • López, Juan Carlos
  • Parras, Francisco José
  • Padilla Ortega, Belén
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Carretero, S.
  • Bellón, José-María|||0000-0002-8492-1565
  • Bermejo, Javier|||0000-0002-5241-2758
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Pascual Pareja, J. Francisco
  • Zamora, Francisco
  • Peña, Jose M.
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Díaz, Marta
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, Jaime|||0000-0001-6934-4619
  • Bustinduy, M.J.
  • Iribarren, José Antonio
  • Rodríguez-Arrondo, F.
  • Eynde, E.Van den
  • Pérez, M.
  • Ribera, E.
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, A.
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Sanfrutos, M.A.
  • Moreno, S.
  • Quereda, Carmen
  • Arranz, A.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Miguel, J.de
  • Schroeder, S.
  • Vergas, J.
  • Téllez, M.J.
  • Vinuesa, D.
  • Muñoz, Lourdes
  • Hernández Quero, José
  • Ferrer, A.
  • Galindo Puerto, María José
  • Ortiz, L.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Montero, M.
  • Blanes, M.
  • Cuellar, S.
  • Lacruz, José
  • Salavert, Miguel|||0000-0002-8571-2124
  • López-Aldeguer, J.
  • Pérez González, Gustavo|||0000-0001-9112-9042
  • Gaspar, G.
  • Yllescas, M.
  • Crespo, P.
  • Aznar, E.
  • Esteban, H.
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Canorea, Isabel
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Quereda, Carmen
  • Sanz, José
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Avellón, Ana|||0000-0003-4425-6350
  • Resino, Salvador|||0000-0001-8783-0450
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Gómez, Josep|||0000-0002-0573-7621
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Ferrando-Martínez, Sara
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • López-Dupla, Miguel
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Leal, Manuel
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Vidal, Francesc|||0000-0002-6692-6186
  • Rull, Anna|||0000-0002-8907-7754
Dyslipidemia in HIV-infected patients is unique and pathophysiologically associated with host factors, HIV itself and the use of antiretroviral therapy (ART). The use of nuclear magnetic resonance spectroscopy (NMR) provides additional data to conventional lipid measurements concerning the number of lipoprotein subclasses and particle sizes. To investigate the ability of lipoprotein profile, we used a circulating metabolomic approach in a cohort of 103 ART-naive HIV-infected patients, who were initiating non-nucleoside analogue transcriptase inhibitor (NNRTI)-based ART, and we subsequently followed up these patients for 36 months. Univariate and multivariate analyses were performed to evaluate the predictive power of NMR spectroscopy. VLDL-metabolism (including VLDL lipid concentrations, sizes, and particle numbers), total triglycerides and lactate levels resulted in good classifiers of dyslipidemia (AUC 0.903). Total particles/HDL-P ratio was significantly higher in ART-associated dyslipidemia compared to ART-normolipidemia (p = 0.001). Large VLDL-Ps were positively associated with both LDL-triglycerides (ρ 0.682, p < 0.001) and lactate concentrations (ρ 0.416, p < 0.001), the last one a marker of mitochondrial low oxidative capacity. Our data suggest that circulating metabolites have better predictive values for HIV/ART-related dyslipidemia onset than do the biochemical markers associated with conventional lipid measurements. NMR identifies changes in VLDL-P, lactate and LDL-TG as potential clinical markers of baseline HIV-dyslipidemia predisposition. Differences in circulating metabolomics, especially differences in particle size, are indicators of important derangements of mitochondrial function that are linked to ART-related dyslipidemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epidemiological survey and risk factors associated with Paslahepevirus balayani in equines in Europe

  • Caballero-Gómez, Javier|||0000-0002-6241-3439
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Cano-Terriza, David|||0000-0001-5657-2567
  • Fajardo, Tomás
  • Buono, Francesco
  • José Cunilleras, Eduard|||0000-0002-4536-7717
  • García Macías, Jesús
  • Alguacil, Eduardo
  • Rivero Román, Antonio|||0000-0002-8643-4250
  • García Bocanegra, Ignacio|||0000-0003-3388-2604
Paslahepevirus balayani (HEV) is an important emerging zoonotic virus in Europe. Although domestic pigs and wild boar are the main reservoirs of this pathogen, susceptibility to this virus has been confirmed in a growing number of animal species, including equines. However, their role in the epidemiology of this virus remains poorly understood. Our aim was to assess HEV circulation and identify potential risk factors associated with exposure in equid species in different European countries. A total of 596 equines, including 496 horses, 63 donkeys and 37 mules/hinnies bred in four European countries (Spain, Italy, United Kingdom and Ireland) were sampled. Thirty-three animals (5.5%; 95%CI: 3.7-7.4) had anti-HEV antibodies. Seropositivity was found in 4.6% of horses, 11.1% of donkeys and 8.1% of mules/hinnies tested. By country, 6.3%, 5.4%, 5.0% and 4.0% of the equines sampled in Spain, Italy, United Kingdom and Ireland, respectively, were seropositive, respectively. Statistical analysis showed that "species" and "drinking water from ponds and streams" were potential risk factors associated with HEV seropositivity in equines in Europe. HEV RNA was not detected in any (0.0%; 95%CI: 0.0-1.8) of the 202 equines tested. Our results provide evidence of a low, spatially homogeneous and widespread viral circulation that is not equal across species in equid populations in the European countries analyzed and indicate that these species appear to play a limited role in the epidemiology of this virus. Further studies are required to elucidate the differences in seroprevalence between donkeys, mules/hinnies and horses and to determine the risk of zoonotic transmission of this pathogen from equid species.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

  • Gatell, José Mª|||0000-0002-4705-3244
  • Assoumou, Lambert
  • Moyle, Graeme
  • Waters, Laura
  • Johnson, Margaret
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Fox, Julie
  • Martínez, Esteban|||0000-0002-6911-8846
  • Stellbrink, Hans-Jürgen
  • Guaraldi, Giovanni|||0000-0002-5724-3914
  • Masia, Mar
  • Gompels, Marl
  • De Wit, Stéphane
  • Florence, Eric|||0000-0002-7004-9120
  • Esser, Stefan
  • Raffi, François
  • Pozniak, Anton L.
To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. Patients were randomized to switch to DTG or to remain on PI/r. Primary endpoints were: proportion maintaining HIV RNA less than 50 copies per ml and percentage change from baseline of total cholesterol at week 48. In total, 415 patients (32 sites in six European countries) were randomized: 205 to DTG and 210 to continue PI/r. About 89% were men, 87% more than 50 years, 74% had a Framingham score more than 10%, with a median CD4 + cell count of 617 cells per μl and suppressed viremia for a median of 5 years. At week 48, in the intent-to-treat analysis, treatment success rate was 93.1% in DTG group and 95.2% in PI/r group (difference -2.1%, 95% confidence interval -6.6 to 2.4, noninferiority demonstrated). There were four virological failures with DTG and one with PI/r with no emergent resistance mutations. There was no significant difference in severe adverse events or grade 3 or 4 adverse events or treatment modifying adverse events. Total cholesterol and other lipid fractions (except high-density lipoprotein cholesterol) improved significantly (P < 0.001) in the DTG group regardless of PI/r at baseline. Switching to a DTG regimen in virologically suppressed HIV type 1 patients with high cardiovascular disease risk was noninferior, and significantly improved lipid profiles.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

  • Masiá, Mar|||0000-0001-9878-2458
  • Padilla Urrea, Sergio|||0000-0002-8420-7310
  • Moreno, Santiago|||0000-0002-2843-1094
  • Barber, Xavier|||0000-0003-3079-5855
  • Iribarren, Jose A.
  • Del Romero, Jorge
  • Gómez-Sirvent, Juan L.
  • Rivero, María
  • Vidal, Francesc|||0000-0002-6692-6186
  • Campins, Antonio A.
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Del Amo, Julia|||0000-0002-3104-540X
  • Dalmau, David|||0000-0003-1936-478X
  • Navarro, Maria Luisa
  • González, Maria Isabel
  • Soriano, Vicente|||0000-0002-4624-5199
  • Garcia, Federico
  • Rubio, Rafael
  • Iribarren, José Antonio
  • Hernández, Beatriz
  • Berenguer, Juan|||0000-0001-8541-8200
  • Sobrino, Paz
  • Hernando, Victoria
  • Alejos, Belén
  • Álvarez, Débora
  • Monge, Susana|||0000-0003-1412-3012
  • Jarrín, Inma|||0000-0002-7485-2252
  • Rivero, Yaiza
  • González, Cristina
  • Muñoz-Fernández, M.Ängeles
  • García-Merino, Isabel
  • Rico, Coral Gómez
  • de la Fuente, Jorge Gallego
  • Torre, Almudena García
  • Portilla, Joaquín|||0000-0002-3676-9511
  • Merino, Esperanza
  • Reus, Sergio|||0000-0002-3320-9754
  • Boix, Vicente|||0000-0002-7015-3948
  • Giner, Livia|||0000-0002-1885-3736
  • Gadea, Carmen
  • Portilla, Irene
  • Pampliega, Maria
  • Díez, Marcos
  • Rodríguez, Juan Carlos
  • Sánchez Payá, José
  • Podzamczer, Daniel|||0000-0001-7090-3561
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Van Den Eyncle, Evan
  • Di Yacovo, Silvana
  • Sumoy, Maria
  • Gómez, Juan Luis
  • Rodríguez, Patricia
  • Alemán, María Remedios
  • del Mar Alonso, María
  • Hernández, María Inmaculada
  • Díaz-Flores, Felicitas
  • García, Dácil
  • Pelazas, Ricardo
  • Labarga, Pablo
  • Barreiro, Pablo|||0000-0002-3819-5371
  • Rivas, Pablo
  • Blanco, Francisco
  • Carbonero, Luz Martín
  • Vispo, Eugenia
  • Solera, Carmen
  • Asensi, Víctor
  • Valle, Eulalia
  • Cartón, José Antonio
  • Pérez, Vicente Estrada
  • Molina, María Jesús Téllez
  • García, Jorge Vergas
  • Carrera, Elisa Pérez-Cecilia
  • Pulido, Federico|||0000-0002-7414-8812
  • Bisbal, Otilia|||0000-0003-3746-3378
  • Matarranz, Mariano
  • Lagarde, Maria
  • Rubio-Martín, Rafael
  • Hernando, Asunción|||0000-0002-1901-1119
  • Portillo, Angel
  • Arrizabalaga, Julio
  • Aramburu, María José
  • Camino, Xabier
  • Rodríguez-Arrondo, Francisco
  • Von Wichmann, Miguel Ángel
  • Tomé, Lidia Pascual
  • Goenaga, Miguel Ángel
  • Bustinduy, M.J.
  • Galparsoro, H.A.
  • Ibarguren, M.
  • Aguado, Mirian
  • Masiá, M.
  • Fernández, Marta
  • García, Elena
  • Navarro, Andrés
  • Montolio, Fernando
  • Robledano, C.
  • Colomé, J.G.
  • Adsuar, Araceli
  • Pascual, R.
  • Muga, Roberto|||0000-0001-6301-431X
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • López Bernaldo de Quirós, Juan Carlos|||0000-0002-8989-9758
  • Miralles, Pilar
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Padilla Ortega, Belén
  • Gijon, Paloma|||0000-0002-5011-1927
  • Carrero, Ana
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Parras, Francisco José
  • Balsalobre, Pascual
  • Diez, Cristina
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso, S.
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • López-Dupla, M.
  • Olona, Montserrat|||0000-0001-5303-9361
  • Aguilar, Alba
  • Sirvent, J.J.
  • Alba, Verónica|||0000-0002-5925-9573
  • Calavia, O.
  • Montero, M.
  • Lacruz, José
  • Blanes, M.
  • Calabuig, Eva|||0000-0002-0177-0037
  • Cuellar, S.
  • López, J.
  • Salavert, Miguel|||0000-0002-8571-2124
  • González García, Juan|||0000-0002-3652-002X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Peña, Jose M.
  • Arribas, Blanca
  • Castro, Juan Miguel
  • Zamora, Francisco
  • Pérez, I.
  • Estébanez, Miriam
  • García Bujalance, Silvia
  • Díaz, Marta
  • Alcáriz, Natalia Stella
  • Mingorance, Jesús|||0000-0001-6173-5711
  • Montero, Dolores
  • González Baeza, Alicia
  • José, Maria Isabel de
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Sanz Sanz, Jesús
  • Salas, A.
  • Sarriá, C.
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Oteo, José A.|||0000-0001-7080-6542
  • Blanco, José Ramón|||0000-0002-4268-0150
  • Ibarra, V.
  • Metola, L.
  • Sanz, M.
  • Pérez-Martínez, L.
  • Pascual, A.
  • Ramos, C.
  • Arazo, P.
  • Gil, D.
  • Rivero, Montserrat|||0000-0002-5834-1559
  • Casado, M.I.
  • Díaz, J.A.
  • Uriz, J.
  • Repáraz, J.
  • Irigoyen, C.
  • Arraiza, M.J.
  • Segura, Ferrán
  • Amengual Guedan, Maria Jose|||0000-0002-5385-3061
  • Navarro Rubio, Gemma|||0000-0002-7195-9046
  • Sala, Montserrat
  • Cervantes Garcia, Manuel|||0000-0001-6073-1110
  • Pineda, Valentí
  • Segura, Victor
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • Antón, Esperanza
  • Nogueras, Maria-Mercedes|||0000-0001-5925-1929
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, Ana
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • López, D.
  • Gutiérrez, Carolina
  • Madrid, N.
  • Lamas, A.
  • Martí, P.
  • De Diaz, A.
  • Serrrano, S.
  • Donat, Lucas
  • Cano, Amanda|||0000-0001-9567-4283
  • Bernal, Enrique|||0000-0002-4041-0579
  • Muñoz, Á.
  • García, F.
  • Hernández Quero, José
  • Peña, Alejandro
  • Muñoz Medina, Leopoldo|||0000-0001-8995-8271
  • Parra, J.
  • Alvarez, Mar|||0000-0003-4590-4401
  • Chueca, Natalia|||0000-0002-3420-3290
  • Guillot, V.
  • Vinuesa, David|||0000-0002-5663-8447
  • Fernández, J.A.
  • Rodríguez, Carmen
  • Puerta, T.
  • Carrió, J.C.
  • Vera, M.
  • Ballesteros, J.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sambeat, Maria Antonia
  • Lamarca, Karuna|||0000-0001-5292-2216
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Fernández-Duran, Irene|||0000-0003-1289-7276
  • Antela, A.
  • Losada, E.
  • Riera, M.
  • Peñaranda, María|||0000-0001-6290-3457
  • Leyes, M.
  • Ribas, M.A.
  • Campins, A.A.
  • Vidal, Carmen|||0000-0003-2768-2710
  • Gil, L.
  • Fanjul, F.
  • Marinescu, C.
  • Ribera, Esteban|||0000-0002-3752-8808
  • Santos, J.
  • Márquez, M.
  • Viciana, I.
  • Palacios, Rosario
  • González, C.M.
  • Viciana, P.
  • Leal, Manuel
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Trastoy, M.
  • Espinosa, Nuria|||0000-0003-2249-2352
Outcomes of people living with HIV (PLWH) developing non-AIDS events (NAEs) remain poorly defined. We aimed to classify NAEs according to severity, and to describe clinical outcomes and prognostic factors after NAE occurrence using data from CoRIS, a large Spanish HIV cohort from 2004 to 2013. Prospective multicenter cohort study. Using a multistate approach we estimated 3 transition probabilities: from alive and NAE-free to alive and NAE-experienced ("NAE development"); from alive and NAE-experienced to death ("Death after NAE"); and from alive and NAE-free to death ("Death without NAE"). We analyzed the effect of different covariates, including demographic, immunologic and virologic data, on death or NAE development, based on estimates of hazard ratios (HR). We focused on the transition "Death after NAE". 8,789 PLWH were followed-up until death, cohort censoring or loss to follow-up. 792 first incident NAEs occurred in 9.01% PLWH (incidence rate 28.76; 95% confidence interval [CI], 26.80-30.84, per 1000 patient-years). 112 (14.14%) NAE-experienced PLWH and 240 (2.73%) NAE-free PLWH died. Adjusted HR for the transition "Death after NAE" was 12.1 (95%CI, 4.90-29.89). There was a graded increase in the adjusted HRs for mortality according to NAE severity category: HR (95%CI), 4.02 (2.45-6.57) for intermediate-severity; and 9.85 (5.45-17.81) for serious NAEs compared to low-severity NAEs. Male sex (HR 2.04; 95% CI, 1.11-3.84), age.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adipokines as New Biomarkers of Immune Recovery, Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy

  • Yeregui, Elena|||0000-0003-2994-4219
  • Masip, Jenifer|||0000-0002-9233-5195
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Blanco, Julià|||0000-0002-2225-0217
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Olona, Montserrat|||0000-0001-5303-9361
  • Vidal-González, Judit
  • Peraire, Maria
  • Martí, Anna
  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Gómez-Bertomeu, Fréderic|||0000-0002-8039-2889
  • Leal, Manuel
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
A significant proportion of people living with HIV (PLHIV) who successfully achieve virological suppression fail to recover CD4 T-cell counts. Since adipose tissue has been discovered as a key immune organ, this study aimed to assess the role of adipokines in the HIV immunodiscordant response. This is a multicenter prospective study including 221 PLHIV starting the first antiretroviral therapy (ART) and classified according to baseline CD4 T-cell counts/µL (controls.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort

  • Suárez-García, Inés|||0000-0002-7016-716X
  • Alejos, Belén
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Iribarren, José Antonio
  • Hernando, Asunción|||0000-0002-1901-1119
  • Ramírez, Margarita
  • Tasias, María
  • Pascual, Mario
  • Jarrín, Inma|||0000-0002-7485-2252
  • Hernando, Victoria
  • Navarro, Maria Luisa
  • González, Maria Isabel
  • Moreno Prieto, Cristina|||0000-0002-3378-3158
  • Iniesta, Carlos|||0000-0002-0928-2679
  • Sousa, Luis Miguel García
  • Perez, Nieves Sanz
  • Rava, Marta|||0000-0003-2260-9370
  • Muñoz Fernández, María Ángeles
  • Consuegra Fernández, Irene
  • Merino, Esperanza
  • García, Gema
  • Portilla, Irene
  • Agea, Iván
  • Portilla, Joaquín|||0000-0002-3676-9511
  • Sánchez Payá, José
  • Rodríguez, Juan Carlos
  • Gimeno, Lina
  • Giner, Livia|||0000-0002-1885-3736
  • Díez, Marcos
  • Carreres, Melissa
  • Reus, Sergio|||0000-0002-3320-9754
  • Boix, Vicente|||0000-0002-7015-3948
  • Torrús-Tendero, Diego
  • Lirola, Ana López
  • García, Dácil
  • Díaz-Flores, Felicitas
  • Gómez, Juan Luis
  • del Mar Alonso, María
  • Pelazas, Ricardo
  • Hernández, Jehovana
  • Alemán, María Remedios
  • Hernández, María Inmaculada
  • Asensi, Victor|||0000-0003-4211-456X
  • Valle, Eulalia
  • Carmenado, Maria Eugenia Rivas
  • Secades, Tomás Suárez Zarracina
  • Is, Laura Pérez
  • Rubio, Rafael
  • Pulido, Federico|||0000-0002-7414-8812
  • Bisbal, Otilia|||0000-0003-3746-3378
  • Domínguez-Domínguez, Lourdes|||0000-0001-6018-9026
  • Crestelo, David Rial
  • Bermejo, Laura
  • Santacreu, Mireia
  • Arrizabalaga, Julio
  • Aramburu, Maria José
  • Camino, Xabier
  • Rodríguez-Arrondo, Francesc
  • Von Wichmann, Miguel Ángel
  • Tomé, Lidia Pascual
  • Goenaga, Miguel Ángel
  • Bustinduy, Maria Jesús
  • Azkune, Harkaitz
  • Ibarguren, Maialen
  • Lizardi, Aitzibir
  • Kortajarena, Xabier
  • Oyaga, Maria Pilar Carmona
  • Igartua, Maitane Umerez
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Masiá, Mar|||0000-0001-9878-2458
  • Padilla Urrea, Sergio|||0000-0002-8420-7310
  • Robledano, Catalina
  • Colomé, Joan Gregori
  • Adsuar, Araceli
  • Pascual, Rafael
  • Fernández, Marta
  • García, José Alberto
  • Barber, Xavier|||0000-0003-3079-5855
  • Re, Vanessa Agullo
  • Abellán, Javier Garcia
  • Pérez, Reyes Pascual
  • Roca, Maria
  • Muga, Roberto|||0000-0001-6301-431X
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Fuster, Daniel|||0000-0003-1262-5860
  • Berenguer, Juan|||0000-0001-8541-8200
  • López Bernaldo de Quirós, Juan Carlos|||0000-0002-8989-9758
  • Gutiérrez, Isabel
  • Padilla Ortega, Belén
  • Gijon, Paloma|||0000-0002-5011-1927
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Parras, Francisco José
  • Balsalobre, Pascual
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso, Sergio
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Olona, Montserrat|||0000-0001-5303-9361
  • Rull, Anna|||0000-0002-8907-7754
  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Alba, Verónica|||0000-0002-5925-9573
  • Castellanos, Alfonso Javier
  • López-Dupla, Miguel
  • Moreno Alonso, Marta
  • Aldeguer, José López
  • Juliá, Marino Blanes
  • Pitarch, Maria Tasias
  • Hernández, Iván Castro
  • Muñoz, Eva Calabuig
  • Tovar, Sandra Cuéllar
  • Lletí, Miguel Salavert
  • Navarro, Juan Fernández
  • González García, Juan|||0000-0002-3652-002X
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Arribas, José Ramón
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Busca, Carmen
  • Cano, Joanna
  • Cardiñanos, Julen
  • Castro, Juan Miguel
  • Delgado Hierro, Ana
  • Escosa García, Luis|||0000-0003-0730-4026
  • Herranz Pinto, Pedro|||0000-0002-9840-6628
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • García Bujalance, Silvia
  • López-Hortelano, Milagros García
  • González Baeza, Alicia
  • Miguel, Rosa de
  • Martín Carbonero, Luz|||0000-0001-8102-4079
  • Mayoral, Mario
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Micán-Rivera, R.|||0000-0002-6626-4266
  • Montejano Sanchez, Rocio|||0000-0002-3446-0545
  • Montes, María Luisa|||0000-0003-1748-813X
  • Moreno, Victoria
  • Pérez Valero, Ignacio|||0000-0002-3488-7135
  • Cebrián, Guadalupe Rúa
  • Rodés, Berta
  • Sainz, Talia|||0000-0002-5301-0945
  • Sendagorta, Elena
  • Valencia, Eulalia|||0000-0001-6902-0120
  • Blanco, José Ramón|||0000-0002-4268-0150
  • Oteo, José A.|||0000-0001-7080-6542
  • Ibarra, Valvanera
  • Metola, Luis
  • Sanz, Mercedes
  • Pérez-Martínez, Laura|||0000-0002-1384-024X
  • Arazo, Piedad
  • Sampériz, Gloria|||0000-0003-0693-2266
  • Dalmau, David|||0000-0003-1936-478X
  • Jaén, Ángels
  • Sanmartí Vilamala, Montserrat|||0000-0002-0432-7073
  • Cairó, Mireia|||0000-0003-2386-2765
  • Martinez-Lacasa, Javier
  • Velli, Pablo
  • Font, Roser
  • Martinez, Marina
  • Aiello, Tommaso Francesco|||0000-0003-4441-6318
  • Marcotegui, Maria Riveiro
  • Repáraz, Jesús
  • Gracia Ruiz de Alda, María
  • De León Cano, María Teresa
  • Pierola Ruiz de Galarreta, Beatriz
  • Amengual Guedan, Maria Jose|||0000-0002-5385-3061
  • Navarro Rubio, Gemma|||0000-0002-7195-9046
  • Garcia, Manel Cervantes
  • Calzado, Sonia|||0000-0002-2975-6448
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Sanz Sanz, Jesús
  • Salas Aparicio, Ana
  • Sarriá Cepeda, Cristina
  • García-Fraile Fraile, Lucio|||0000-0002-2512-6107
  • Martín Gayo, Enrique|||0000-0002-2619-6086
  • Moreno, Santiago|||0000-0002-2843-1094
  • Casado Osorio, José Luis
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno Zamora, Ana
  • Gutiérrez, Carolina
  • Madrid, Nadia
  • del Campo, Santos|||0000-0003-2234-5432
  • Serrano-Villar, Sergio|||0000-0002-5447-3554
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Martínez Sanz, Javier|||0000-0003-2020-3908
  • Anxa Urroz, Usua
  • Velasco, Tamara
  • Bernal, Enrique|||0000-0002-4041-0579
  • Cano Sánchez, Alfredo
  • Alcaraz García, Antonia
  • Bravo Urbieta, Joaquín|||0000-0003-2079-0305
  • Muñoz Perez, Ángeles
  • Alcaraz, Maria Jose
  • Villalba, Maria del Carmen
  • García, Federico
  • Quero, José Hernández
  • Muñoz Medina, Leopoldo|||0000-0001-8995-8271
  • Álvarez, Marta
  • Chueca, Natalia|||0000-0002-3420-3290
  • Vinuesa, David|||0000-0002-5663-8447
  • Martinez-Montes, Clara
  • Guerrero Beltrán, Carlos
  • de Salazar, Adolfo|||0000-0002-4318-858X
  • Fuentes López, Ana
  • Del Romero Guerrero, Jorge|||0000-0001-8922-5182
  • Raposo Utrilla, Montserrat
  • Rodríguez, Carmen
  • Puerta, Teresa
  • Carrió, Juan Carlos
  • Vera, Mar|||0000-0002-3841-7747
  • Ballesteros, Juan
  • Ayerdi, Oskar|||0000-0002-9441-8031
  • Antela, Antonio
  • Losada, Elena
  • Riera, Melchor
  • Peñaranda, María|||0000-0001-6290-3457
  • Ribas, Maria Àngels
  • Campins, Antoni A.
  • Vidal Lampurdanés, Carmen|||0000-0001-5843-8038
  • Fanjul, Francisco
  • Murillas, Javier|||0000-0003-2169-7110
  • Homar, Francisco|||0000-0003-0116-3277
  • Vilchez, Helem H.
  • Martin, Maria Luisa
  • Payeras, Antoni
  • Santos, Jesús
  • Gómez Ayerbe, Cristina
  • Viciana, Isabel
  • Palacios, Rosario
  • López, Carmen Pérez
  • González Domenec, Carmen María
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Espinosa, Nuria|||0000-0003-2249-2352
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Podzamczer, Daniel|||0000-0001-7090-3561
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Tiraboschi, Juan Manuel|||0000-0002-0073-873X
  • Silva, Ana
  • Saumoy, Maria|||0000-0002-0047-1991
  • Prieto, Paula
  • Ribera, Esteban|||0000-0002-3752-8808
  • Curran, Adrian|||0000-0002-1263-0814
  • Olalla Sierra, Julián
  • Pérez Stachowski, Javier|||0000-0002-5189-1953
  • del Arco Jiménez, Alfonso|||0000-0002-5432-4591
  • De La Torre, Javier
  • Prada, José Luis
  • García de Lomas Guerrero, José María|||0000-0001-8160-8488
  • Martínez, Onofre Juan
  • Vera, Francisco Jesús
  • Martínez, Lorena
  • García, Josefina
  • Alcaraz, Begoña
  • Jimeno, Amaya
  • Castro Iglesias, Angeles|||0000-0002-8418-9749
  • Pernas Souto, Berta|||0000-0002-2061-3096
  • Mena de Cea, Álvaro
  • Muñoz, Josefa
  • Zuriñe Zubero, Miren
  • Baraia-Etxaburu, Josu Mirena
  • Ugarte, Sofia Ibarra
  • Ferrero Beneitez, Oscar Luis
  • López de Munain, Josefina
  • Cámara López, Maria Mar
  • De La Peña, Mireia
  • López, Miriam
  • López Azkarreta, Iñigo
  • Galera, Carlos
  • Albendin, Helena
  • Pérez, Aurora
  • Iborra, Asunción
  • Moreno, Antonio
  • Merlos, Maria Angustias
  • Vidal, Asunción
  • Meca, Marisa
  • Amador, Concha|||0000-0003-0843-8624
  • Pasquau, Francisco
  • Ena, Javier|||0000-0002-1181-7396
  • Benito, Concha
  • Fenoll, Vicenta
  • Gil Anguita, Concepción
  • Algado Rabasa, José Tomás
  • Malmierca Corral, Eduardo|||0000-0002-4071-7247
  • González-Ruano, Patricia|||0000-0003-0395-7740
  • Rodrigo, Dolores Martín
  • Ruiz Seco, María Pilar
  • Mohamed-Balghata, Mohamed Omar
  • Gómez Vidal, María Amparo
  • De Zarraga, Miguel Alberto
  • Estrada, Vicente|||0000-0002-7795-5986
  • Téllez Molina, María Jesús
  • Vergas García, Jorge
  • Pérez-Somarriba Moreno, Juncal|||0000-0002-9623-5781
  • Górgolas, Miguel
  • Cabello-Ubeda, Alfonso|||0000-0001-8429-8358
  • Álvarez, Beatriz
  • Prieto, Laura
  • Sanz Moreno, José
  • Arranz Caso, Alberto
  • Hernández Gutiérrez, Cristina
  • Novella Mena, María
  • Galindo Puerto, María José
  • Vilalta, Ramón Fernando
  • Ferrer Ribera, Ana
  • Rivero Román, Antonio|||0000-0002-8643-4250
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • López López, Pedro|||0000-0001-5740-6675
  • Machuca Sánchez, Isabel|||0000-0003-3343-0085
  • Frias Casas, Mario
  • Camacho Espejo, Angela
  • Cervero Jiménez, Miguel|||0000-0001-9387-7917
  • Torres Perea, Rafael
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Rincón Mayo, Pilar
  • Macías, Juan|||0000-0002-4778-790X
  • Merchante, Nicolás|||0000-0003-1120-8942
  • Real, Luis M.|||0000-0003-4932-7429
  • Corma Gómez, Anaïs|||0000-0002-1078-0237
  • Fernández Fuertes, Marta
  • Gonzalez-Serna, Alejandro|||0000-0002-0239-8417
  • Poveda, Eva|||0000-0003-4835-9875
  • Pérez González, Alexandre|||0000-0003-4836-6768
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Morano, Luis
  • Miralles, Celia
  • Ocampo Hermida, Antonio|||0000-0002-3176-9758
  • Pousada, Guillermo|||0000-0002-2466-8094
Background: To estimate the prevalence and severity of menopausal symptoms and anxiety/depression and to assess the differences according to menopausal status among women living with HIV aged 45-60 years from the cohort of Spanish HIV/AIDS Research Network (CoRIS). Methods: Women were interviewed by phone between September 2017 and December 2018 to determine whether they had experienced menopausal symptoms and anxiety/depression. The Menopause Rating Scale was used to evaluate the prevalence and severity of symptoms related to menopause in three subscales: somatic, psychologic and urogenital; and the 4-item Patient Health Questionnaire was used for anxiety/depression. Logistic regression models were used to estimate odds ratios (ORs) of association between menopausal status, and other potential risk factors, the presence and severity of somatic, psychological and urogenital symptoms and of anxiety/depression. Results: Of 251 women included, 137 (54.6%) were post-, 70 (27.9%) peri- and 44 (17.5%) pre-menopausal, respectively. Median age of onset menopause was 48 years (IQR 45-50). The proportions of pre-, peri- and post-menopausal women who had experienced any menopausal symptoms were 45.5%, 60.0% and 66.4%, respectively. Both peri- and post-menopause were associated with a higher likelihood of having somatic symptoms (aOR 3.01; 95% CI 1.38-6.55 and 2.63; 1.44-4.81, respectively), while post-menopause increased the likelihood of having psychological (2.16; 1.13-4.14) and urogenital symptoms (2.54; 1.42-4.85). By other hand, post-menopausal women had a statistically significant five-fold increase in the likelihood of presenting severe urogenital symptoms than pre-menopausal women (4.90; 1.74-13.84). No significant differences by menopausal status were found for anxiety/depression. Joint/muscle problems, exhaustion and sleeping disorders were the most commonly reported symptoms among all women. Differences in the prevalences of vaginal dryness (p = 0.002), joint/muscle complaints (p = 0.032), and sweating/flush (p = 0.032) were found among the three groups. Conclusions: Women living with HIV experienced a wide variety of menopausal symptoms, some of them initiated before women had any menstrual irregularity. We found a higher likelihood of somatic symptoms in peri- and post-menopausal women, while a higher likelihood of psychological and urogenital symptoms was found in post-menopausal women. Most somatic symptoms were of low or moderate severity, probably due to the good clinical and immunological situation of these women.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez de Ory, Santiago
  • Ramos, José Tomas
  • Fortuny, Clàudia
  • González-Tomé, María Isabel
  • Mellado, Maria José
  • Moreno, David
  • Frick, Marie Antoinette
Retrospective study; Spanish Paediatric HIV Network; Rates of perinatal HIV, Estudio retrospectivo; Red Española de VIH Pediátrico; Tasas de VIH perinatal, Estudi retrospectiu; Xarxa espanyola de VIH Pediàtrica; Taxes de VIH perinatal, Background: There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods: A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results: A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions: A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact., This work has been partially funded by Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035, RD12/0017/0037 and RD16/0025/0019), project as part of the Plan R+D+I (2008-2011; 2013-2016) and cofinanced by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER), RISEPICLIN-19/2015, Fondo para la Investigación Sanitaria of the Spanish Ministry of Science and Innovation (FIS PI13/00422, PI16/01863), CYTED (214RT0482) and EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. COST CA17140 Cancer Nanomedicine-Front The Bench to Bebside. We thank the Spanish HIV HGM BioBank supported by ISC III project RETIC PT13/0010/0028 and PT17/0015/0042. No funding for this work was received from National Institutes of Health (NIH), Wellcome Trust and Howard Hughes Medical Institute (HHMI)